Legend Biotech Corp (LEGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 350M 700M 1.1B Q4 '23: 285.1M Q1 '24: 264.3M Q2 '24: 284.2M Q3 '24: 205.6M Q4 '24: 627.3M Q1 '25: 621.2M Q2 '25: 563.3M Q3 '25: 556.4M Q4 '25: 1B Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Gross Profit TTM

0 250M 500M 750M Q4 '23: 140.9M Q1 '24: 106.6M Q2 '24: 113.8M Q3 '24: 26.2M Q4 '24: 410.9M Q1 '25: 384.4M Q2 '25: 277M Q3 '25: 209.4M Q4 '25: 631.7M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q2 '23: -532.1M Q3 '23: -509.3M Q4 '23: -518.3M Q1 '24: -466M Q2 '24: -285.1M Q3 '24: -348.2M Q4 '24: -177M Q1 '25: -218.1M Q2 '25: -325.3M Q3 '25: -239.7M Q4 '25: -296.8M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Cost of Revenue TTM

0 150M 300M 450M Q2 '23: 116.7M Q3 '23: 134.7M Q4 '23: 144.2M Q1 '24: 157.7M Q2 '24: 170.4M Q3 '24: 179.4M Q4 '24: 216.4M Q1 '25: 236.8M Q2 '25: 286.3M Q3 '25: 347.1M Q4 '25: 397.1M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q2 '23: -358.6M Q3 '23: -347.4M Q4 '23: -393.3M Q1 '24: -238.6M Q2 '24: -142.7M Q3 '24: -157.6M Q4 '24: -144M Q1 '25: -263.3M Q2 '25: -274.7M Q3 '25: -170M Q4 '25: -100.2M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q2 '23: -378.1M Q3 '23: -369.7M Q4 '23: -413.4M Q1 '24: -260.6M Q2 '24: -162.1M Q3 '24: -173.7M Q4 '24: -158.1M Q1 '25: -273.1M Q2 '25: -290.3M Q3 '25: -188.6M Q4 '25: -128.8M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '23: 330.5M Q1 '24: 364M Q2 '24: 365.2M Q3 '24: 366.6M Q1 '25: 367.5M Q2 '25: 368.3M Q3 '25: 369.3M Q1 '23 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q4 '23: -1.47 Q1 '24: -1.29 Q2 '24: -0.77 Q3 '24: -0.95 Q4 '24: -0.48 Q1 '25: -0.59 Q2 '25: -0.88 Q3 '25: -0.65 Q4 '25: -0.81 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.